人民财讯8月10日电，长青股份（002391）8月10日晚间披露2025年半年度报告，上半年实现营业收入 20.83亿元，同比增长7.28%；归母净利润4227.78万元，同比增长117.75%；基本每股收益0.07元。 ...

Core Points - Jiangsu Changqing Agricultural Chemical Co., Ltd. reported a revenue of 2,082.97 million yuan for the first half of 2025, representing a year-on-year increase of 7.28% [7] - The net profit attributable to shareholders reached 42.28 million yuan, showing a significant growth of 117.75% compared to the same period last year [7] - Total assets as of June 30, 2025, amounted to 9,714.20 million yuan, an increase of 12.42% from the beginning of the year, while net assets attributable to shareholders grew by 0.58% to 4,252.98 million yuan [7] Financial Performance - Revenue for the reporting period was 2,082,974,025.02 yuan, compared to 1,941,669,462.02 yuan in the previous year [4] - The net profit attributable to shareholders was 42,277,788.13 yuan, up from 19,415,486.52 yuan, marking a 117.75% increase [4] - Basic earnings per share rose to 0.0676 yuan, reflecting a 114.60% increase from 0.0315 yuan [4] Operational Highlights - The company actively engaged in international markets, responding to a rebound in pesticide demand by optimizing product structure and accelerating overseas market registration [7] - Efforts to reduce costs and improve efficiency were implemented through process optimization, technological upgrades, and management enhancements [7] - The production capacity at the Jiangsu plant was effectively released to meet market demands [7]

Core Viewpoint - Jiangsu Changqing Agricultural Chemical Co., Ltd. held its third meeting of the ninth board of directors on August 7, 2025, where several key resolutions were passed, including the approval of the 2025 semi-annual report and the special report on the use of raised funds [1][2]. Group 1: Meeting Resolutions - The board approved the 2025 semi-annual report and its summary, which will be published on August 11, 2025 [1][2]. - The board approved the special report on the storage and use of raised funds for the first half of 2025, also to be published on August 11, 2025 [2]. - The board approved the proposal to cancel the supervisory board and amend the company’s articles of association, which will be submitted for review at the first extraordinary general meeting of 2025 [2][3]. - The board approved the proposal to formulate and amend certain governance systems, with the full text to be published on August 11, 2025 [3]. - The board approved the proposal to change part of the investment projects funded by raised funds, which will also be submitted for review at the first extraordinary general meeting of 2025 [4]. - The board decided to hold the first extraordinary general meeting of 2025 on September 5, 2025, combining on-site and online voting [5].

Core Points - The company held the third meeting of the ninth supervisory board on August 7, 2025, where all members confirmed the authenticity and completeness of the disclosed information [1][2] - The supervisory board approved the 2025 semi-annual report and its summary, affirming that the report accurately reflects the company's actual situation without any misleading statements [1][2] - The board also approved the special report on the use of raised funds for the first half of 2025, confirming compliance with relevant regulations [2] - A proposal to change part of the investment projects funded by raised funds was approved, specifically changing the project from "annual production of 3,500 tons of glyphosate raw materials" to "annual production of 1,000 tons of prothioconazole raw materials" and "annual production of 4,200 tons of pyrethroid series products" [2][3] - The decision to change the investment projects is based on the company's actual situation and is expected to improve the efficiency of fund usage and optimize resource allocation [2][3]

Meeting Information - The company will hold its first extraordinary general meeting of shareholders in 2025 on September 5, 2025, at 14:00 [1] - The meeting will include both on-site and online voting options for shareholders [2][4] Voting Procedures - Shareholders can vote in person or authorize others to attend and vote on their behalf [2][3] - Online voting will be available through the Shenzhen Stock Exchange system and internet platform from 9:15 to 15:00 on the meeting day [1][4] Shareholder Eligibility - All shareholders registered with the China Securities Depository and Clearing Corporation Limited by the end of trading on September 1, 2025, are eligible to attend the meeting [2][3] Agenda Items - The meeting will review proposals that comply with the Company Law and the company's articles of association [2][3] - Specific proposals will be detailed in the official announcements published on August 11, 2025 [2] Registration Process - Individual shareholders must present their ID and securities account card for registration, while representatives must provide additional documentation [3][4] - Remote shareholders can register via mail or fax before the deadline of September 4, 2025 [3] Additional Information - The company has provided detailed instructions for online voting and registration in the attached documents [4][5]

General Overview - The document outlines the working rules of the Compensation and Assessment Committee of Jiangsu Changqing Agricultural Chemical Co., Ltd, approved on August 7, 2025, during the third meeting of the ninth board of directors [1] Composition of the Committee - The Compensation and Assessment Committee consists of three directors, with independent directors making up more than half and serving as the convener [2] - Committee members are nominated by the chairman, more than half of the independent directors, or more than one-third of the directors, and elected by the board [2] Responsibilities and Authority - The committee is responsible for establishing assessment standards for directors and senior management, reviewing compensation policies, and making recommendations on various matters including compensation and incentive plans [2][3] - The board has the authority to reject any compensation plans that may harm shareholder interests, and any unadopted recommendations must be documented and disclosed [3] Decision-Making Procedures - The human resources department coordinates the preparation for the committee's decisions, providing necessary financial and performance data [3] - The evaluation process for directors and senior management includes self-assessment and performance evaluation based on established standards [3] Meeting Rules - The committee holds regular meetings at least once a year, with notifications sent seven days in advance, and can convene temporary meetings as needed [4] - A quorum requires attendance from at least two-thirds of the members, and decisions must be approved by a majority [4] Confidentiality and Reporting - All attendees of the committee meetings are bound by confidentiality regarding the discussed matters [5] - Resolutions and voting results from the meetings must be reported in writing to the board of directors [5]

Summary of Key Points Core Viewpoint The company, Jiangsu Changqing Agricultural Chemical Co., Ltd., is changing part of its fundraising investment projects to optimize its industrial layout and improve the efficiency of fund usage in response to market conditions and strategic planning [1][10]. Group 1: Fundraising Overview - The company issued 9.138 million convertible bonds with a total fundraising amount of 913.8 million yuan, net of issuance costs [1][2]. - The funds were initially allocated for various projects, including the production of herbicides and pesticides [2]. Group 2: Project Change Details - The project "Annual Production of 3,500 Tons of Glyphosate Raw Material" will be changed to "Annual Production of 1,000 Tons of Prothioconazole Raw Material" and "Annual Production of 4,200 Tons of Pyrethroid Series Products" [3][4]. - The change represents 30.79% of the total fundraising amount [3]. Group 3: Market Context - Glyphosate has seen a significant drop in price from 270,000 yuan/ton in 2022 to below 50,000 yuan/ton currently due to increased competition and market saturation [4]. - The global market for Prothioconazole reached 1.328 billion USD in 2023, indicating strong demand for this product [4]. Group 4: New Project Financials - The Prothioconazole project has a total investment of 147 million yuan, with expected annual sales revenue of 119.3 million yuan and a net profit of 30.16 million yuan upon reaching full production [5][8]. - The Pyrethroid project has a total investment of 120 million yuan, with projected annual sales revenue of 109 million yuan and a net profit of 26.86 million yuan [6][8]. Group 5: Approval Process - The board of directors approved the project changes on August 7, 2025, and the changes will be submitted for shareholder approval [9][10]. - The changes comply with relevant regulations and do not harm the interests of the company or its shareholders [10][11].

Group 1 - The company reported a revenue of 2.083 billion yuan for the first half of the year, representing a year-on-year growth of 7.28% [1] - The net profit attributable to shareholders reached 42.78 million yuan, a significant increase of 117.75% compared to 19.42 million yuan in the same period last year [1] - The basic earnings per share were 0.0676 yuan [1]

Core Points - The company announced that its ninth board meeting was held on August 7, 2025, to review the 2025 semi-annual report and its summary [2] Summary by Category - **Company Announcement** - The company held its ninth board meeting on August 7, 2025, in a physical format [2] - The meeting included the review of the 2025 semi-annual report and its summary [2]

民生证券股份有限公司 关于江苏长青农化股份有限公司变更部分募集资金投资项目的 核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为江苏长青 农化股份有限公司（以下简称"长青股份"或"公司"）持续督导的保荐机构，民生 证券根据《证券发行上市保荐业务管理办法》《深圳证券交易所上市规则》《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》、《深圳证券 交易所上市公司自律监管指引第 13 号——保荐业务》、《深圳证券交易所上市公 司自律监管指引第 1 号——主板上市公司规范运作》等相关法律法规的规定和要 求，通过定期的现场检查、资料查阅、沟通访谈及列席重要会议等方式，对长青 股份变更部分募集资金投资项目事项进行了核查，具体情况如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于核准江苏长青农化股份有限公司公开发行 可转换公司债券的批复》（证监许可[2018]2097 号）核准，公司于 2019 年 2 月 27 日向社会公开发行 913.8 万张可转换公司债券，每张面值 100 元，公开发行可转 债募集资金总额为 913,800,000.00 元，扣除承销费、保荐费等 ...